

## Reliably Genotype the Poly-T Repeats in TOMM40

Alzheimer's Disease (AD) is now the most common cause of dementia worldwide, affecting over 46M people. These numbers are expected to increase dramatically, reaching nearly 75M people by 2030<sup>1</sup>. Given this growing human and healthcare burden, the need to identify potential biomarkers for early detection and risk assessment remains a major focus.

Multiple studies have implicated the poly-T length polymorphism, rs10524523 ('523), of the *TOMM40* gene in the age of onset of AD. The AmplideX PCR/CE *TOMM40* Kit (RUO) is the first clinical research tool that accurately resolves the poly-T polymorphism at the *TOMM40* '523 locus and provides researchers with a reliable and reproducible assay to advance the understanding of the role of this gene in AD.



Figure 1: AmplideX PCR/CE TOMM40 Kit<sup>\*</sup> components



#### **REDUCED COMPLEXITY**

Simplified analysis of the TOMM40 gene

- First-ever kitted and distributed solution
- Easy-to-interpret results

#### **OPTIMIZED WORKFLOW**

Streamlined, rapid and reliable workflow

- Validated protocol ensures reproducible results
- Minimal hands-on and TAT (Figure 2)

#### **QUALITY PERFORMANCE**

Greater sensitivity and accuracy than currently available methods

- 1 base pair resolution for poly-T sizing ensures accurate results at key genotypic boundaries
- Reliable and accurate results every time




Figure 2: AmplideX PCR/CE TOMM40 Kit\* workflow

<sup>1</sup>Source: World Alzheimer Report 2015 | \*For research use only. Not for use in diagnostic procedures.



# **Amplide**X<sup>®</sup> PCR/CE TOMM40 Kit\*

### **ANALYTICAL CHARACTERISTICS OF AMPLIDEX PCR/CE TOMM40 KIT (RUO)**



within 1 bp (7/8 = 48 Ts; 1/8 = 47 Ts)

管 93 645 50 28


barcelona@rafer.es

94 499 85 80

■ bilbao@rafer.es

**e** 981 93 89 26


galicia@rafer.es



🕾 96 340 48 00

levante@rafer.es

sevilla@rafer.es



2500-0668

■ lisboa@rafer.es



malaga@rafer.es